Currently Viewing:
Currently Reading
Can Rituximab Delay Disease Progression in SPMS?
January 19, 2019 – Samantha DiGrande
Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy
January 19, 2019 – Jaime Rosenberg
Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose
January 19, 2019 – Laura Joszt
PCT Just as Effective as MASCC for Predicting Serious Complications in Febrile Neutropenia
January 18, 2019 – Jaime Rosenberg
Researchers Document Links Between Pollution Levels, ED Visits for Breathing Problems
January 18, 2019 – Allison Inserro
CMS Expands VBID in Medicare Advantage, Increases Risk Sharing in Part D
January 18, 2019 – Allison Inserro
Tracking Medicaid Expansion
January 18, 2019 – AJMC Staff
This Week in Managed Care: January 18, 2019
January 18, 2019
USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer
January 18, 2019 – Samantha DiGrande

AHA, Google Life Sciences Announce $50M Collaboration to Find Drivers of Heart Disease

Mary K. Caffrey
The venture will select a project leader in early 2016. AHA said this is the largest single research investment in its history.
The American Heart Association (AHA) and Google Life Sciences on Sunday announced a $50 million partnership to fund research into the causes of heart disease. Each organization will invest $25 million in the effort, which AHA said is the largest one-time research investment in the group’s history.

The announcement came in an afternoon session at AHA’s Scientific Sessions, which opened Saturday and conclude Wednesday in Orlando, Florida.

According to a statement from AHA, in early 2016, a joint leadership group of AHA and Google Life Sciences members will select a point person to run the venture. The statement said the person may be a cardiologist but could come from another field, will receive control of the $50 million in phases to run the program.

It was described as a “cross functional group of investigators, and lead all efforts towards further finding new causes and drivers of coronary heart disease.” Aspects will cover clinical research, engineering, and data analysis, as well as access to support from both Google Life Sciences and AHA.

“With its devastating human impact on countless generations of families, cardiovascular disease, and in particular coronary heart disease remains the greatest and deadliest global health challenge we face today,” said AHA CEO Nancy Brown.

Sunday’s announcement emphasized the role that technology will play in the project. “This is a fundamentally different kind of model for funding innovation,” said Andy Conrad, CEO of Google Life Sciences. “The team leader will be able to bring together clinicians, engineers, designers, basic researchers and other experts to think in new ways about the causes of coronary heart disease.”

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!